The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial
- 1 June 2017
- journal article
- research article
- Published by Elsevier in Genetics in Medicine
- Vol. 19 (6) , 683-690
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Regulation, Reimbursement, and the Long Road of Implementation of Personalized Medicine—A Perspective from the United StatesValue in Health, 2013
- Current Methodological Issues in the Economic Assessment of Personalized MedicineValue in Health, 2013
- Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperiencePLOS ONE, 2013
- Molecular diagnostics and personalized medicine in oncology: Challenges and opportunitiesJournal of Cellular Biochemistry, 2012
- Active home-based cancer treatmentJournal of Multidisciplinary Healthcare, 2012
- Next‐generation sequencing: ready for the clinics?Clinical Genetics, 2012
- The real cost of sequencing: higher than you think!Genome Biology, 2011
- Predictive value of KRAS mutations in chemoresistant CRCNature Reviews Clinical Oncology, 2009
- Advantages and limitations of next‐generation sequencing technologies: A comparison of electrophoresis and non‐electrophoresis methodsElectrophoresis, 2008
- Next-Generation DNA Sequencing MethodsAnnual Review of Genomics and Human Genetics, 2008